Literature DB >> 1672860

Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.

A H Raimundo1, D H Patil, P G Frost, D B Silk.   

Abstract

The effect of sulphasalazine and olsalazine on jejunal and ileal water and electrolyte absorption was investigated in normal subjects by a steady state intestinal perfusion of a physiological glucose bicarbonate electrolyte solution in the absence and presence of increasing concentrations of each drug. (Olsalazine 0.25 g/l, 1.0 g/l, jejunum; 0.5 g/l, 1.0 g/l, ileum; sulphasalazine 0.25 g/l, 0.5 g/l, 2.0 g/l jejunum; 1.0 g/l, 2.0 g/l, ileum.) In the jejunum olsalazine at 1.0 g/l significantly inhibited water, sodium, chloride, and potassium absorption (p less than 0.05). In the ileum olsalazine at 0.5 and 1 g/l significantly inhibited glucose uptake (p less than 0.04) and water absorption (p less than 0.03). In the jejunum sulphasalazine had a dose related and significant inhibitory effect on water, bicarbonate, and sodium absorption and at 2.0 g/l an inhibitory effect on chloride, potassium (p less than 0.005), and glucose (p less than 0.05) absorption. In the ileum sulphasalazine had no significant effect on water and electrolyte absorption. All inhibitory effects were rapidly reversible. These data show that unexplained diarrhoea in patients with ulcerative colitis treated with olsalazine may occur as a consequence of inhibition of water and electrolyte absorption in the small intestine and that the mechanisms of inhibition of sulphasalazine and olsalazine are different.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672860      PMCID: PMC1378832          DOI: 10.1136/gut.32.3.270

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

2.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

3.  Desensitization of patients with inflammatory bowel disease to sulfasalazine.

Authors:  S L Taffet; K M Das
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

4.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

5.  A method for studying absorption of water and solute from the human small intestine.

Authors:  H Cooper; R Levitan; J S Fordtran; F J Ingelfinger
Journal:  Gastroenterology       Date:  1966-01       Impact factor: 22.682

6.  Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.

Authors:  H Sandberg-Gertzén; M Ryde; G Järnerot
Journal:  Scand J Gastroenterol       Date:  1983-01       Impact factor: 2.423

7.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

8.  Influence of olsalazine on gastrointestinal transit in ulcerative colitis.

Authors:  S S Rao; N W Read; C D Holdsworth
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

9.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

10.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

View more
  5 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

3.  Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

Authors:  S P Travis; C Tysk; H J de Silva; H Sandberg-Gertzén; D P Jewell; G Järnerot
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

Review 4.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Site-dependent small intestinal absorption of ranitidine.

Authors:  T Gramatté; E el Desoky; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.